Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

PCSK9 and Atherosclerosis - Lipids and Beyond.

Shapiro MD, Fazio S.

J Atheroscler Thromb. 2017 May 1;24(5):462-472. doi: 10.5551/jat.RV17003. Epub 2017 Mar 9.

2.

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL.

Cardiovasc Res. 2016 Oct;112(1):429-42. doi: 10.1093/cvr/cvw194. Epub 2016 Aug 5. Review.

PMID:
27496869
3.

On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.

Tavori H, Rashid S, Fazio S.

Atherosclerosis. 2015 Feb;238(2):264-70. doi: 10.1016/j.atherosclerosis.2014.12.017. Epub 2014 Dec 17. Review.

4.

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.

Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.

Circulation. 2014 Jul 29;130(5):431-41. doi: 10.1161/CIRCULATIONAHA.113.006720. Epub 2014 May 23. Erratum in: Circulation. 2015 May 5;131(18):e429.

5.

Improved recovery and identification of membrane proteins from rat hepatic cells using a centrifugal proteomic reactor.

Zhou H, Wang F, Wang Y, Ning Z, Hou W, Wright TG, Sundaram M, Zhong S, Yao Z, Figeys D.

Mol Cell Proteomics. 2011 Oct;10(10):O111.008425. doi: 10.1074/mcp.O111.008425. Epub 2011 Jul 12.

6.

Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.

Johnson LA, Altenburg MK, Walzem RL, Scanga LT, Maeda N.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1745-52. doi: 10.1161/ATVBAHA.108.169680. Epub 2008 Jul 10.

7.

Familial hypercholesterolaemia.

Marais AD.

Clin Biochem Rev. 2004 Feb;25(1):49-68.

8.

Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB.

Blasiole DA, Oler AT, Attie AD.

J Biol Chem. 2008 Apr 25;283(17):11374-81. doi: 10.1074/jbc.M710457200. Epub 2008 Feb 13.

9.
10.

Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase.

Sparks JD, Collins HL, Chirieac DV, Cianci J, Jokinen J, Sowden MP, Galloway CA, Sparks CE.

Biochem J. 2006 Apr 15;395(2):363-71.

11.

Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA.

J Clin Invest. 2004 May;113(9):1277-87.

12.

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Rader DJ, Cohen J, Hobbs HH.

J Clin Invest. 2003 Jun;111(12):1795-803. Review. No abstract available.

13.

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Horton JD, Goldstein JL, Brown MS.

J Clin Invest. 2002 May;109(9):1125-31. Review. No abstract available.

Supplemental Content

Support Center